Descripción de la empresa
iSpecimen Inc. operates a specialized marketplace designed to facilitate the provision of biospecimens to life science researchers operating globally. This business model functions within the broader Healthcare sector, specifically targeting the Diagnostics & Research industry, which is critical for advancing medical knowledge and drug development. The company currently holds a market capitalization of $1.41M and reported annual revenue of $1.93M, while the specific employee count is not publicly disclosed in available data. These valuation and revenue figures indicate that iSpecimen Inc. occupies a niche position within the market, reflecting a small-scale operation with limited market penetration relative to larger healthcare conglomerates. The proprietary online platform connects medical researchers requiring access to subjects, samples, and data directly with hospitals, thereby streamlining the supply chain for biological materials essential for scientific inquiry.
Salud financiera
The company reported a revenue of $1.93M over the trailing twelve months, yet generated a net income of $-10,487,532, revealing a severe disconnect between top-line sales and profitability. This substantial gap between revenue and net income indicates an extremely fragile cost structure where operating expenses significantly outweigh earnings before interest and taxes. The EBITDA stands at $-8,717,890, further confirming that the core business operations are currently burning cash rather than generating operational profit. Additionally, free cash flow is negative at $-2,782,585, which signifies a lack of financial flexibility and an inability to fund capital expenditures or operations from internal cash generation. The gross margin is recorded at 1.2%, suggesting that the cost of goods sold consumes nearly all of the revenue generated before accounting for operating expenses. Furthermore, the operating margin is a staggering -5192.9% and the profit margin is 0.0%, indicating that the company is not covering its fixed costs and is effectively losing money on every dollar of revenue. In terms of solvency, the company holds $6.88M in cash against $268,798 in debt, but the debt-to-equity ratio is 8.70, implying a highly leveraged balance sheet relative to equity. The current ratio is 1.12, which suggests that the company has just enough current assets to cover its current liabilities, leaving little room for error in short-term liquidity management. Finally, the return on equity is -327.8% and the return on assets is -59.4%, metrics that reveal management is currently destroying shareholder value and utilizing assets inefficiently.
Evaluación de valoración
The trailing P/E ratio is not available (N/A) due to the lack of positive earnings, while the forward P/E is listed as -0.18, implying that the market expects earnings to remain negative in the near term. The price-to-book ratio stands at 0.46, indicating that the market values the company at less than half of its net asset value, which often reflects high perceived risk or a lack of tangible growth prospects. The price-to-sales ratio is 0.73 and the EV/EBITDA is 0.27, suggesting that the valuation is extremely low relative to sales and enterprise value metrics, though these figures must be interpreted with caution given the negative earnings profile. The stock's 52-week high is $3.18 and the 52-week low is $0.14, meaning the current price sits significantly below the peak performance of the last year. The beta value is 1.98, which indicates that the stock price is nearly twice as volatile as the broader market, exposing investors to substantial fluctuations in share price driven by market sentiment. These alternative valuation metrics and volatility measures suggest that the stock is priced for distress rather than traditional growth or stability.
Growth & Income
Revenue growth year-over-year is -96.5%, while earnings growth is not available (N/A) due to the negative earnings position. This negative revenue trajectory indicates that the company is shrinking rapidly, and since there are no positive earnings to compare, the relationship between earnings and revenue growth cannot be analyzed in a standard comparative manner. As a non-dividend payer, the company has a dividend yield of N/A and a payout ratio of 0.0%, meaning no cash is distributed to shareholders as the firm reinvests all available capital into its operations or attempts to cover operational deficits. Consequently, the overall growth and income profile is characterized by significant revenue contraction and a complete absence of dividend income, reflecting a business currently in a survival or restructuring phase rather than an expansion phase.